Citation: Gandy S, Petanceska S (2005) Authors' Reply. PLoS Med 2(3): e85. https://doi.org/10.1371/journal.pmed.0020085
Published: March 29, 2005
Copyright: © 2005 Gandy and Petanceska. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests: The authors haves declared that no competing interests exist.
We appreciate the note from Drs. Koudinov and Berezov . In our opinion, no model has yet been presented that plausibly accounts for all the data on statins, cholesterol, amyloid-ß protein (Aß), and Alzheimer disease. In our paper , we present evidence that the isoprenoid pathway contributes to statin-activated shedding of the APP ectodomain in cultured cells. We do not yet know which (if any) other “cholesterol-related” Alzheimer phenomena are also attributable to modulation of isoprenoids, Rho, or ROCK.
Previously, conventional wisdom held that Aß load and hypercholesterolemia were directly related, based on observations that high-fat diet aggravated amyloid pathology in plaque-forming mice [3,4,5]. More recently, however, the formulation that statins act simply via cholesterol-lowering fails to account for several observations that cannot immediately be reconciled, either with the original “dogma” or with each other.
First, Fagan et al.  questioned the role of cholesterol as the final common pathway in Aß load specification, since, in their experiments, low cholesterol per se apparently had no impact on brain Aß load in plaque-forming transgenic mice. Then, equally puzzling pharmacological data emerged. Atorvastatin was shown to lower brain amyloid load and Aß levels, but brain cholesterol levels were unaffected by the drug . In an apparent complete contradiction with the original observations, now, some investigators have been able to devise circumstances under which there is an inverse relationship between cholesterol and Aß, with low neuronal cholesterol increasing Aß generation , and vice versa . These newer observations are unexpected and extremely puzzling, and no comprehensive explanation has yet emerged.
For those readers seeking an update on this challenging area, we would direct your attention to the Alzheimer Research Forum Web page (http://www.alzforum.org/new/detailprint.asp?id=1135), where you will find an excellent review of the literature as well as a series of evaluations of how our data fit into existing scenarios and models regarding cholesterol, statins, cerebral amyloidosis, and the cognitive failure of Alzheimer disease.
- 1. Koudinov AR, Berezov TT (2005) Cholesterol, statins, and Alzheimer disease. PLoS Med 2(3): e81.AR KoudinovTT BerezovCholesterol, statins, and Alzheimer disease.PLoS Med200523e81
- 2. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, et al. (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2: e18.S. PedriniTL CarterG. PrendergastS. PetanceskaME EhrlichModulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK.PLoS Med20052e18
- 3. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, et al. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321–331.LM RefoloB. MalesterJ. LaFrancoisT. Bryant-ThomasR. WangHypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model.Neurobiol Dis20007321331
- 4. Levin-Allerhand JA, Lominska CE, Smith JD (2002) Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging 6: 315–319.JA Levin-AllerhandCE LominskaJD SmithIncreased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet.J Nutr Health Aging20026315319
- 5. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13: 455–459.FS ShieLW JinDG CookJB LeverenzRC LeBoeufDiet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice.Neuroreport200213455459
- 6. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, et al. (2004) ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165: 1413–1422.AM FaganE. ChristopherJW TaylorM. ParsadanianM. SpinnerApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.Am J Pathol200416514131422
- 7. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, et al. (2002) Statin therapy for Alzheimer's disease: Will it work? J Mol Neurosci 19: 155–161.SS PetanceskaS. DeRosaV. OlmN. DiazA. SharmaStatin therapy for Alzheimer's disease: Will it work?J Mol Neurosci200219155161
- 8. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, et al. (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953–960.J. Abad-RodriguezMD LedesmaK. CraessaertsS. PergaM. MedinaNeuronal membrane cholesterol loss enhances amyloid peptide generation.J Cell Biol2004167953960
- 9. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, et al. (2004) APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 16: 124–132.AJ GeorgeRM HolsingerCA McLeanKM LaughtonK. BeyreutherAPP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease.Neurobiol Dis200416124132